"Renewing our SOC 2 Type II audit is an important validation of the security framework we've established at Yosi Health," ...
Abivax is advancing obefazimod, a first-in-class oral therapy for UC and CD, with major upcoming data catalysts. Click here ...
Sanofi’s Sarclisa subcutaneous formulation administered via on-body injector recommended for EU approval by the CHMP to treat multiple ...
APEX Part A data demonstrated durable maintenance of response at 52-weeks for every 3- and 6-months dosing, respectively, including:- 75% and 85% ...
San Marcos nonprofit Wounded Warrior Homes is expanding housing and mental health services for veterans, including a brain ...
Dr. Ajay Nooka, director of the Myeloma program at Winship Cancer Institute of Emory University, simplifies the International ...
Apogee Therapeutics shares rally as Phase 2 APEX data show durable atopic dermatitis control with 3- or 6-month dosing.
When Aardvark Therapeutics announced earlier this month that it was pausing a phase 3 trial of its lead metabolic candidate, ...
With thoracic oncology in the middle of a combinatorial revolution—EGFR-targeted doublets and triplets, a maturing ...
Apogee Therapeutics has published phase 2 eczema data that suggest its anti-IL-13 antibody is a threat to Eli Lilly, ...
APEX Part A data demonstrated durable maintenance of response at 52-weeks for every 3- and 6-months dosing, respectively, ...
Product sales and commercial rights revenues in 2025 increased 90% year-over-year to US$82.1 million (RMB574.1 million)Sales ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results